company background image
CUV logo

Clinuvel Pharmaceuticals ASX:CUV Stok Raporu

Son Fiyat

AU$13.73

Piyasa Değeri

AU$685.8m

7D

-5.3%

1Y

-11.9%

Güncellenmiş

04 Nov, 2024

Veri

Şirket Finansalları +

Clinuvel Pharmaceuticals Limited

ASX:CUV Stok Raporu

Piyasa değeri: AU$685.8m

CUV Stoklara Genel Bakış

Bir biyofarmasötik şirketi olan Clinuvel Pharmaceuticals Limited, Avustralya, Avrupa, Amerika Birleşik Devletleri, İsviçre ve uluslararası alanda genetik, metabolik, sistemik ve yaşamı tehdit eden bozuklukları olan hastalar için tedaviler geliştirmeye ve ticarileştirmeye odaklanmaktadır.

Clinuvel Pharmaceuticals Limited Rakipler

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Clinuvel Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse FiyatıAU$13.73
52 Haftanın En Yüksek SeviyesiAU$18.20
52 Haftanın En Düşük SeviyesiAU$12.96
Beta0.92
11 Aylık Değişim-2.56%
3 Aylık Değişim0%
1 Yıllık Değişim-11.87%
33 Yıllık Değişim-57.82%
5 Yıllık Değişim-56.88%
Halka arzdan bu yana değişim1,273.00%

Son Haberler & Güncellemeler

Recent updates

If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Aug 11
If EPS Growth Is Important To You, Clinuvel Pharmaceuticals (ASX:CUV) Presents An Opportunity

Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Jun 27
Calculating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?

May 09
Is Now The Time To Put Clinuvel Pharmaceuticals (ASX:CUV) On Your Watchlist?

Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Mar 24
Estimating The Intrinsic Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Nov 18
An Intrinsic Calculation For Clinuvel Pharmaceuticals Limited (ASX:CUV) Suggests It's 41% Undervalued

Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Oct 20
Increases to Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Compensation Might Cool off for now

Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

Jul 30
Is Clinuvel Pharmaceuticals Limited (ASX:CUV) Trading At A 21% Discount?

Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

Feb 27
Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Could Be 27% Below Their Intrinsic Value Estimate

Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

Dec 14
Does Clinuvel Pharmaceuticals (ASX:CUV) Deserve A Spot On Your Watchlist?

This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

Nov 03
This Is The Reason Why We Think Clinuvel Pharmaceuticals Limited's (ASX:CUV) CEO Might Be Underpaid

A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Sep 23
A Look At The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

Jul 23
Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today

With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Apr 10
With EPS Growth And More, Clinuvel Pharmaceuticals (ASX:CUV) Is Interesting

Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

Mar 06
Have Insiders Sold Clinuvel Pharmaceuticals Limited (ASX:CUV) Shares Recently?

Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

Feb 27
Earnings Miss: Clinuvel Pharmaceuticals Limited Missed EPS By 41% And Analysts Are Revising Their Forecasts

What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?

Feb 20
What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?

Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain

Feb 01
Clinuvel Pharmaceuticals (ASX:CUV) Shareholders Have Enjoyed A Whopping 648% Share Price Gain

Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

Jan 14
Estimating The Fair Value Of Clinuvel Pharmaceuticals Limited (ASX:CUV)

We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide

Dec 28
We Wouldn't Rely On Clinuvel Pharmaceuticals's (ASX:CUV) Statutory Earnings As A Guide

Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 10
Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition

Nov 21
What You Need To Know About Clinuvel Pharmaceuticals Limited's (ASX:CUV) Investor Composition

Hissedar Getirileri

CUVAU BiotechsAU Pazar
7D-5.3%-3.7%-1.1%
1Y-11.9%19.0%16.1%

Getiri vs. Endüstri: CUV underperformed the Australian Biotechs industry which returned 19% over the past year.

Getiri vs Piyasa: CUV underperformed the Australian Market which returned 16.1% over the past year.

Fiyat Oynaklığı

Is CUV's price volatile compared to industry and market?
CUV volatility
CUV Average Weekly Movement5.1%
Biotechs Industry Average Movement10.4%
Market Average Movement8.6%
10% most volatile stocks in AU Market17.5%
10% least volatile stocks in AU Market3.6%

İstikrarlı Hisse Senedi Fiyatı: CUV has not had significant price volatility in the past 3 months compared to the Australian market.

Zaman İçindeki Volatilite: CUV's weekly volatility (5%) has been stable over the past year.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
1999n/aPhilippe Wolgenwww.clinuvel.com

Bir biyofarmasötik şirketi olan Clinuvel Pharmaceuticals Limited, Avustralya, Avrupa, Amerika Birleşik Devletleri, İsviçre ve uluslararası alanda genetik, metabolik, sistemik ve yaşamı tehdit eden bozuklukları olan hastalar için tedaviler geliştirmeye ve ticarileştirmeye odaklanmaktadır. Şirketin öncü ilaç adayı, eritropoietik protoporfirisi (EPP) olan yetişkin hastalarda fototoksisitenin önlenmesi için sistemik bir fotokoruyucu ilaç olan SCENESSE'dir. Şirketin boru hattı ürünleri arasında her ikisi de alfa-melanosit uyarıcı hormon analoğu olan CUV9900 ve Parvysmelanotide (VLRX001); ve afamelanotide'in sıvı enjekte edilebilir bir formülasyonu olan PRÉNUMBRA bulunmaktadır.

Clinuvel Pharmaceuticals Limited Temel Bilgiler Özeti

Clinuvel Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CUV temel i̇stati̇sti̇kler
Piyasa değeriAU$685.77m
Kazançlar(TTM)AU$35.64m
Gelir(TTM)AU$88.18m

19.2x

F/K Oranı

7.8x

P/S Oranı

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CUV gelir tablosu (TTM)
GelirAU$88.18m
Gelir MaliyetiAU$7.73m
Brüt KârAU$80.45m
Diğer GiderlerAU$44.81m
KazançlarAU$35.64m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)0.71
Brüt Marj91.23%
Net Kâr Marjı40.41%
Borç/Özkaynak Oranı0%

CUV uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

0.4%

Mevcut Temettü Verimi

7%

Ödeme Oranı